Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OURBIOTIC: BB-12 Probiotic for Antibiotic-Associated Diarrhea
NCT04414722Phase 1Completed
- Sponsor
- Georgetown University
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised trial of bifidobacterium animalis subsp. lactis bb-12 in antibiotic-associated diarrhea (AAD), sponsored by Georgetown University. Started Jan 2021; status: completed.
02
Drugs
bifidobacterium animalis subsp. lactis bb-12
03
Conditions
antibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on NCT04414722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414722.